Clinical Trials Logo

Pancreatic Neoplasms clinical trials

View clinical trials related to Pancreatic Neoplasms.

Filter by:

NCT ID: NCT03281382 Completed - Clinical trials for Metastatic Pancreatic Cancer

Phase 1 Trial of Interleukin 12 Gene Therapy for Metastatic Pancreatic Cancer

Start date: July 1, 2017
Phase: Phase 1
Study type: Interventional

This phase 1 trial will investigate the toxicity of combining interleukin 12 gene therapy with standard chemotherapy in metastatic pancreatic cancer.

NCT ID: NCT03261947 Completed - Colorectal Cancer Clinical Trials

A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors

Start date: October 25, 2017
Phase: Phase 2
Study type: Interventional

The purpose of this study is to confirm the safety and tolerability of TAK-931 in a cohort of Western participants with metastatic solid tumors and to evaluate the anti-tumor activity of TAK-931 in participants with metastatic pancreatic cancer, colorectal cancer (CRC), squamous esophageal cancer (sqEC), and squamous non-small-cell lung cancer (sqNSCLC).

NCT ID: NCT03250273 Completed - Pancreatic Cancer Clinical Trials

A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma

Start date: November 6, 2017
Phase: Phase 2
Study type: Interventional

The proposed study is an open-label, two-arm study of entinostat plus nivolumab in patients with unresectable or metastatic cholangiocarcinoma (CCA) or pancreatic ductal adenocarcinoma (PDAC).

NCT ID: NCT03239184 Completed - Clinical trials for Unresectable Pancreatic Cancer

Bioinformation Therapy for Pancreatic Cancer

Start date: September 1, 2017
Phase: Phase 2/Phase 3
Study type: Interventional

The aim of this study is the synergistic effect of cancer ablation and life information rehabilitation therapy on unresectable pancreatic cancer.

NCT ID: NCT03207724 Completed - Pancreatic Cancer Clinical Trials

Study of Onivyde and 5-FU in Combination With Xilonix for Pancreatic Cancer With Cachexia

OnFX
Start date: October 16, 2017
Phase: Phase 1
Study type: Interventional

This study is being conducted to examine the safety of the investigational drug, Xilonix(™), in addition to standard doses of Onivyde® (nanoliposomal irinotecan) and 5- fluorouracil (5FU)/folinic acid (leucovorin) for pancreatic cancer patients with cachexia. Cachexia is a syndrome that includes involuntary weight loss and physical deterioration that can contribute to poor outcomes of cancer treatment. In other studies, Xilonix has increased lean body mass in advanced cancer patients. This increase could lead to improved weight maintenance and quality of life.

NCT ID: NCT03205176 Completed - Breast Cancer Clinical Trials

AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas

Start date: June 30, 2017
Phase: Phase 1
Study type: Interventional

This is a first-time-in-man (FTIM) multicenter, dose escalation study designed to investigate the safety, pharmacokinetics, and pharmacodynamics of AZD5153 in patients with malignant solid tumors, including lymphomas.

NCT ID: NCT03200821 Completed - Pancreatic Cancer Clinical Trials

An Open Label Study to Evaluate G17DT Compared to Gemcitabine

Start date: August 14, 2000
Phase: Phase 3
Study type: Interventional

In this study 250 µg of G17DT was administered at Weeks 0, 2 and 6 in order to demonstrate non inferiority compared to gemcitabine in prolonging survival in advanced pancreatic cancer.

NCT ID: NCT03199586 Completed - Breast Cancer Clinical Trials

Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies

Start date: December 21, 2017
Phase: Phase 1
Study type: Interventional

Phase 1 A: First-in-human phase 1 study to determine safety of NP-G2-044 when given orally on a daily X 28 days followed by a 14 day rest period.

NCT ID: NCT03190265 Completed - Pancreatic Cancer Clinical Trials

Study of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cy) in Patients With Pancreatic Cancer

Start date: December 14, 2017
Phase: Phase 2
Study type: Interventional

The purpose of this study is to study the safety and clinical activity of nivolumab and ipilimumab in combination with either sequential administration of CY/GVAX pancreas vaccine followed by CRS-207 (Arm A) or with administration of CRS-207 alone (Arm B) in patients with pancreatic cancer.

NCT ID: NCT03189914 Completed - Clinical trials for Metastatic Pancreatic Cancer

RX-3117 in Combination With Abraxane® in Subjects With Metastatic Pancreatic Cancer

Start date: October 2, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

This will be a Phase 1b/2a multicenter 2-stage study. Phase 1 will be conducted as a dose-finding, open-label study of oral RX-3117 administered in combination with Abraxane® to subjects with metastatic pancreatic cancer. After completion of the Phase 1 portion, a Phase 2a study will be conducted using a 2 stage, open-label design, of RX 3117 and Abraxane® in combination to treat subjects with metastatic pancreatic cancer as first line therapy.